ArticleCanadian journal of gastroenterology & hepatology2026
Optimising Blood Test Monitoring Frequency for Inflammatory Bowel Disease Patients: Balancing Adherence, Comfort and Risk.
Article in Canadian journal of gastroenterology & hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Optimising Blood Test Monitoring Frequency for Inflammatory Bowel Disease Patients: Balancing Adherence, Comfort and Risk.Canadian journal of gastroenterology & hepatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInflammatory bowel disease (IBD) therapies can cause myelosuppression and hepatitis. The European Crohn's and Colitis Organisation (ECCO) recommends 3-monthly blood test monitoring; however, these recommendations are largely based on expert consensus, and real-world evidence informing optimal long-term monitoring intervals remains limited.
aimTo determine the incidence of medication-related hepatitis and myelosuppression in a population-based IBD cohort and estimate the laboratory monitoring burden required to detect clinically significant adverse events.
methodsA retrospective cohort study was performed using the Manawatū IBD incidence cohort. Patients diagnosed with IBD between 1 January 2011 and 31 December 2015 were followed longitudinally until 31 December 2022. Medication exposure, laboratory results, and clinical outcomes were recorded. Hepatitis was defined as alanine aminotransferase (ALT) > 2 × the upper limit of normal, while myelosuppression was defined as a neutrophil count < 1.0 × 10
resultsAmong 204 incident cases, 12 were excluded due to prediagnosis hepatitis or myelosuppression, leaving 192 patients for analysis. Twenty-four hepatitis events and two myelosuppression events were observed during 1739 patient-years of follow-up. 6-mercaptopurine (hazard ratio [HR] 39.2, p < 0.001), azathioprine (HR 6.26, p = 0.002), methotrexate (HR 9.94, p = 0.004) and lower mean corpuscular volume (HR 0.89, p = 0.001) were independently associated with hepatitis. Following the initial 6 months of therapy, one hepatitis event was detected for every 33 patient-years of stable thiopurine exposure monitored with routine quarterly blood testing.
conclusionClinically significant hepatitis and myelosuppression were uncommon in this population-based IBD cohort, particularly after the initial 6 months of therapy. These findings suggest that reduced laboratory monitoring frequency in carefully selected patients with established treatment stability warrants evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.